Bausch Health Cos Inc. (NYSE:BHC) Receives $8.00 Average PT from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been given a consensus rating of “Reduce” by the five brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.00.

Several research analysts have commented on BHC shares. Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th.

Insider Activity at Bausch Health Cos

In related news, Director Frank D. Lee sold 24,456 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director directly owned 49,339 shares in the company, valued at $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after purchasing an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after acquiring an additional 4,910 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after acquiring an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC acquired a new stake in Bausch Health Cos in the fourth quarter valued at approximately $59,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Trading Down 1.1%

Shares of NYSE BHC opened at $4.86 on Friday. The firm has a 50 day moving average price of $5.19 and a two-hundred day moving average price of $5.73. The stock has a market cap of $1.82 billion, a P/E ratio of -1.50 and a beta of 0.42. Bausch Health Cos has a 52-week low of $4.57 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.37 billion. As a group, equities analysts forecast that Bausch Health Cos will post 4.05 EPS for the current year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.